Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

To assess pharamcokinetics, safety and tolerability of a single oral dose of BKM120 in subjects with mild, moderate and severe hepatic impairment

Phase 1

Novartis Pharmaceuticals